Durable response to lenalidomide in a patient with myelodysplastic syndrome associated with isolated 5q deletion and JAK2 V617F mutation despite discontinuation of treatment

about

Coincidence of 5q deletion and the JAK2V617F mutation: report of two patients with overlapping myelodysplastic and myeloproliferative features and review of the literature.

P2860

Q49362075-9B97A99D-2D7C-4102-BCE7-B5469E36FD6D

P2860

Durable response to lenalidomide in a patient with myelodysplastic syndrome associated with isolated 5q deletion and JAK2 V617F mutation despite discontinuation of treatment

Item

http://www.wikidata.org/entity/Q37001825

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 20 April 2016

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Durable response to lenalidomi ...... e discontinuation of treatment

@en

Durable response to lenalidomi ...... discontinuation of treatment.

@nl

type

Item

label

Durable response to lenalidomi ...... e discontinuation of treatment

@en

Durable response to lenalidomi ...... discontinuation of treatment.

@nl

prefLabel

Durable response to lenalidomi ...... e discontinuation of treatment

@en

Durable response to lenalidomi ...... discontinuation of treatment.

@nl

P1476

Durable response to lenalidomi ...... e discontinuation of treatment

@en

P2093

Amalia Vassou

http://www.w3.org/2001/XMLSchema#string

Dora Gougopoulou

http://www.w3.org/2001/XMLSchema#string

Eleftheria Hatzimichael

http://www.w3.org/2001/XMLSchema#string

Evangelos Briasoulis

http://www.w3.org/2001/XMLSchema#string

Konstantinos Lagos

http://www.w3.org/2001/XMLSchema#string

P2860

International scoring system for evaluating prognosis in myelodysplastic syndromes

Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders

Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion.

Long-Term Response in a Patient with del(5q) Myelodysplastic Syndrome Who Discontinued Lenalidomide and Obtained a Good Response and Tolerance to Rechallenge.

Myelodysplastic disorders carrying both isolated del(5q) and JAK2(V617F) mutation: concise review, with focus on lenalidomide therapy

Treatment with lenalidomide does not appear to increase the risk of progression in lower risk myelodysplastic syndromes with 5q deletion. A comparative analysis by the Groupe Francophone des Myelodysplasies.

Practical recommendations on the use of lenalidomide in the management of myelodysplastic syndromes.

Unraveling the molecular pathophysiology of myelodysplastic syndromes.

Response to lenalidomide in a patient with myelodysplastic syndrome with isolated del(5q) and JAK2 V617F mutation.

JAK2(V617F) mutation in myelodysplastic syndrome (MDS) with del(5q) arises in genetically discordant clones.

P304

23-26

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3892/MCO.2016.866

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Alexandra Papoudou-Bai

P577

2016-04-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27330758

http://www.w3.org/2001/XMLSchema#string

P932

4906970

http://www.w3.org/2001/XMLSchema#string

Durable response to lenalidomide in a patient with myelodysplastic syndrome associated with isolated 5q deletion and JAK2 V617F mutation despite discontinuation of treatment

about

P2860

P2860

Durable response to lenalidomide in a patient with myelodysplastic syndrome associated with isolated 5q deletion and JAK2 V617F mutation despite discontinuation of treatment

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P932